Nasdaq:US$38.93 (+1.39) | HKEX:HK$60.10 (+0.40) | AIM:£5.56 (+0.14)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
Announcement & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
Announcement & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
News & Presentations
Hutchmed
| News & Presentations
Key RNS & Press Releases
13 Sep 2021
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma
Read more
8 Sep 2021
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Read more
7 Sep 2021
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference
Read more
6 Sep 2021
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
Read more
Presentations & Publications
17 Sep 2021
ESMO2021: An Phase Ib/II Study of Fruquintinib in Combination with Tislelizumab in Patients with Advanced Triple Negative Breast Cancer
Read more
28 Jul 2021
2021 Half-Year Financial Results
Read more
22 Jun 2021
The Lancet Respiratory Medicine: Savolitinib in Chinese NSCLC patients harbouring MET exon 14 skipping alterations
Read more
18 Jun 2021
Corporate Presentation
Read more
Other UK Regulatory Notices
2 Sep 2021
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Read more
1 Sep 2021
Monthly Return
Read more
31 Aug 2021
Total Voting Rights
Read more
17 Aug 2021
Electronic Communication of Corporate Information
Read more
17 Aug 2021
Election of language and means of receipt of corporate communications
Read more
4 Aug 2021
Monthly Return
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.